Incyte Q4 EPS Falls Short by $0.12 Despite 27.8% Revenue Gain
Incyte reported Q4 2025 adjusted EPS of $1.80, missing estimates by $0.12, while revenue surged 27.8% year-over-year to $1.51 billion. Operating margin contracted to 22.3% from 25.6%, triggering an 8.8% share price decline in morning trading.
1. Q4 2025 Financial Results
Incyte posted adjusted EPS of $1.80 for Q4 2025, missing consensus by $0.12, and achieved revenue of $1.51 billion, up 27.8% year-over-year, driven by strong product sales.
2. Operating Margin Compression
The company's operating margin declined to 22.3% from 25.6% in the prior year period, reflecting higher R&D and SG&A expenses outpacing revenue growth.
3. Stock Reaction and Outlook
Shares fell 8.8% in morning trading following the mixed results, as investors weighed the earnings miss against robust top-line growth; market watchers will monitor whether cost controls can restore margin expansion.